

AMENDMENTS TO THE SPECIFICATION

Please replace section 3 of Example 1, as set forth on page 31 of the Examples with the following:

3. Anti-ataxin1 siRNA targeting the mRNA sequence at sites numbered 2750 - through 2770:

SEQ ID:5[[4]] 5' - AACCAAGTACCGTCCACATTCC - 3'

SEQ ID:6 3' - GGTCAATGCAGGTGTAAAGGAA - 5'

A series of six deoxyoligonucleotide fragments were designed, ordered and purchased from MWG Biotech, Inc., a custom oligonucleotide synthesis service to provide the six fragments making up the three target sites. Additionally, these oligonucleotides were constructed to include an 8 base sequence complementary to the 5' end of the T7 promoter primer included in an siRNA construction kit (Ambion, Inc. catalog number 1620). Each specific oligonucleotide was annealed to the supplied T7 promoter primer, and filled-in with Klenow fragment to generate a full-length DNA template for transcription into RNA. Two *in vitro* transcribed RNAs (one an antisense to the other) were generated by *in vitro* transcription reactions then hybridized to each other to make double-stranded RNA. The double-stranded RNA product was treated with DNase (to remove the DNA transcription templates) and RNase (to polish the ends of the double-stranded RNA), and column purified to provide the three siRNAs that were delivered and tested in cells.